<DOC>
	<DOCNO>NCT02648438</DOCNO>
	<brief_summary>This open-label , partially randomize , four-period study healthy male subject assess bioavailability pharmacokinetics single dose AZD7594 administer intravenously , orally inhale via two different dry powder inhaler ( DPIs ) pressurize meter-dose inhaler ( pMDI )</brief_summary>
	<brief_title>A Study Assess Bioavailability Compare Pharmacokinetics AZD7594 Inhaled Via Monodose Inhaler Multiple-dose Dry Powder Inhalers ( DPI ) Pressurized Metered-dose Inhaler ( pMDI ) Healthy Male Subjects</brief_title>
	<detailed_description>This study open-label , partially randomize , 4-period , 5-treatment study healthy male subject , perform single study center . All subject receive 4 5 treatment . The IV infusion fix first treatment ( Period 1 ) , Monodose inhaler fix second treatment ( Period 2 ) oral formulation fix fourth treatment ( Period 4 ) . During Period 3 , subject split 2 equal cohort , multiple-dose DPI pMDI .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Provision sign date , write informed consent prior study specific procedure . 2 . Healthy male subject age 18 45 year suitable vein cannulation repeat venipuncture . 3 . Have body mass index ( BMI ) 18 30 kg/m2 , inclusive , weigh least 50 kg . 4 . Subjects willing follow reproductive restriction prevent pregnancy drug exposure female partner refrain donate sperm father child first day dose 3 month last dose investigational product . 5 . Be able inhale dry powder inhaler ( DPI ) device pressurize metereddose inhaler ( pMDI ) device accord give instruction . 1 . History clinically significant disease disorder , opinion Investigator , may either put volunteer risk participation study , influence result volunteer 's ability participate study . 2 . History presence gastrointestinal ( GI ) , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion drug . 3 . Any clinically significant illness , major medical/surgical procedure , trauma within 4 week first administration Investigational medicinal product ( IMP ) . 4 . Any clinically significant abnormality clinical chemistry , hematology , urinalysis result screen checkin , judge investigator . 5 . Any clinically significant abnormal finding vital sign 5 minute rest screen checkin , judge investigator , define follow : Systolic blood pressure ( BP ) &gt; 140 mm Hg ; Systolic BP &lt; 90 mm Hg ; Diastolic BP &gt; 90 mm Hg ; Diastolic BP &lt; 60 mm Hg ; Heart rate &lt; 40 &gt; 85 beat per minute ( bpm ) . 6 . Any clinically significant abnormities physical examination lung function , judge investigator . 7 . Any clinically significant abnormality 12lead electrocardiogram ( ECG ) screen checkin , judge investigator . 8 . Any clinically important abnormality rhythm , conduction morphology rest ECG may interfere interpretation QTc ( QT interval correct ) interval change . This include subject follow : Clinically significant PR ( PQ ) ( ECG interval measure onset P wave onset QRS complex ) interval prolongation ; Intermittent persistent second third degree AV block ; Persistent intermittent complete bundle branch block ( BBB ) , incomplete bundle branch block ( IBBB ) , intraventricular conduction delay ( IVCD ) QRS ( ECG interval measure onset QRS complex J point ) &gt; 110 m . Subjects QRS &gt; 110 m &lt; 115 m acceptable evidence , example , ventricular hypertrophy preexcitation ; Abnormal T wave morphology , particularly protocol define primary lead . 9 . Prolonged QTcF ( QT interval correct heart rate use Fridericia 's formula ) &gt; 450 msec family history long QT ( ECG interval measure onset QRS complex end T wave ) syndrome . 10 . Known suspected history drug abuse , judge investigator 11 . Current smoker smoke used nicotine product within previous 3 month . 12 . History alcohol abuse excessive intake alcohol judge investigator . 13 . Positive screen drug abuse , alcohol , cotinine screen admission study center . 14 . History severe allergy/hypersensitivity ongoing allergy/hypersensitivity , judge investigator history hypersensitivity drug similar chemical structure class AZD7594 excipients . 15 . Excessive intake caffeine contain drink e.g. , coffee , tea , caffeine contain energy drink cola ( total 3 cup per day ) . 16 . Use drug enzymeinducing property St John 's Wort within 3 week prior first administration IMP . 17 . Use prescribed nonprescribed medication include vaccine , antacid , analgesic ( paracetamol/acetaminophen ) , herbal remedy , vitamin mineral 2 week prior first administration IMP long medication long halflife . Occasional use paracetamol/acetaminophen allow minor pain headache ( 3000 mg/day ) . 18 . Plasma donation within 1 month screen blood donation/loss 500 mL 3 month prior screen . 19 . Has participate clinical study investigate clinical evaluation method 1 month ( least 5 halflives ) prior administration investigational product . 20 . Known Gilbert 's syndrome , family history Gilbert 's syndrome suspicion Gilbert 's syndrome base liver function test . 21 . Any contraindication use vagolytic sympaticomimetic drug , judge investigator . 22 . Involvement AstraZeneca , PAREXEL study site employee close relative . 23 . Any positive result screen serum hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody human immunodeficiency virus ( HIV ) antibody . 24 . Judgment investigator subject participate study ongoing recent ( i.e. , screen period ) minor medical complaint may interfere interpretation study data consider unlikely comply study procedure , restriction requirement . 25 . Vulnerable subject , e.g. , keep detention , protect adult guardianship , trusteeship , committed institution governmental juridical order .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>AZD7594</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Healthy male subject</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Monodose inhaler</keyword>
	<keyword>Multiple-dose dry powder inhaler</keyword>
</DOC>